MedRhythms

MedRhythms is a pioneering digital therapeutics company dedicated to developing next-generation neurotherapeutics to enhance walking, mobility, and related functional outcomes for individuals with neurologic injuries and diseases. The company's proprietary, patented platform is built upon an evidence-based intervention known as Rhythmic Auditory Stimulation (RAS), which has been supported by over three decades of clinical research. This innovative approach integrates sensors, software, and music with advanced neuroscience to directly target and engage neural circuitry. MedRhythms is actively creating a robust pipeline of digital therapeutics to address a variety of neurological conditions, including stroke, multiple sclerosis, and Parkinson's disease. The company's mission is to make its transformative digital therapeutics accessible to everyone who needs them, regardless of their proximity to a clinical setting, thereby improving the lives of millions affected by walking disabilities.

Founded in 2015 out of Spaulding Rehabilitation Hospital, one of the nation's leading rehabilitation facilities, MedRhythms has established itself as a leader in the field. The company's lead product, InTandem®, which targets chronic stroke walking deficits, received Breakthrough Device designation from the FDA in 2020. To further its mission, MedRhythms has entered into a significant collaboration with Universal Music Group, providing patients with access to a vast and culturally diverse collection of music to enhance their therapeutic experience. The company's commitment to innovation and patient-centered care is driven by a passionate and dedicated team with expertise in clinical applications, technology, and business. Headquartered in Portland, Maine, MedRhythms fosters a flexible, hybrid work environment with team members across the United States, all united by the goal of revolutionizing brain health and restoring function for patients worldwide.